Risk Based Monitoring
– Multicenter Phase 1 study to evaluate IO-108 as monotherapy and in combination with an anti-PD-1 – – IO-108 is Company’s second program to advance to clinic – Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that…
Read More
Meaghan Powers, lead consultant, Halloran Consulting Group penned an excellent article on integrating Quality Management with RBM Meaghan tackles a number topics in the 3 Key Steps To Successful Execution. First, a risk assessment must be conducted both pre-study and ongoing during the trial. Second, a well-articulated study protocol should be developed based on factors…
Read More